Whittier Trust Co. Boosts Stake in Danaher Co. (NYSE:DHR)

Whittier Trust Co. increased its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 3.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 127,040 shares of the conglomerate's stock after acquiring an additional 4,157 shares during the quarter. Whittier Trust Co.'s holdings in Danaher were worth $35,318,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tsfg LLC increased its stake in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate's stock worth $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Danaher in the second quarter valued at $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the 1st quarter worth $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in Danaher in the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Price Performance

DHR traded down $2.12 during midday trading on Monday, hitting $272.26. The stock had a trading volume of 2,358,310 shares, compared to its average volume of 2,716,144. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The business has a fifty day moving average of $270.82 and a 200 day moving average of $260.34. The company has a market cap of $201.66 billion, a P/E ratio of 46.15, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm's quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.05 EPS. As a group, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher's dividend payout ratio is presently 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company's stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 in the last ninety days. 11.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DHR shares. Barclays lifted their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a "neutral" rating in a report on Wednesday, July 24th. Robert W. Baird lifted their price target on Danaher from $271.00 to $278.00 and gave the company an "outperform" rating in a research report on Wednesday, July 24th. Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the company an "outperform" rating in a research note on Wednesday, July 24th. Finally, Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.